EcoDrugPlus

Gamma-Aminobutyric Acid Receptor Subunit Beta-2-Like

Ensembl ID : ENSSTUG00000003134
Gene Symbol: LOC115167402
3 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSSTUG00000027559
Gene Symbol: GABRA2
3 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSSTUG00000042105
Gene Symbol: GABRA2
3 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSSTUG00000010615
Gene Symbol: GABRA3
3 Cross references
192 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSSTUG00000021892
Gene Symbol: GABRA3
3 Cross references
192 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSSTUG00000039620
Gene Symbol: GABRA5
3 Cross references
197 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSSTUG00000016656
Gene Symbol: GABRA5
3 Cross references
197 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSSTUG00000026521
Gene Symbol: GABRA5
3 Cross references
205 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6

Ensembl ID : ENSSTUG00000010760
Gene Symbol: GABRA6
3 Cross references
188 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6

Ensembl ID : ENSSTUG00000021207
Gene Symbol: GABRA6
3 Cross references
189 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta1

Ensembl ID : ENSSTUG00000035832
Gene Symbol: GABRB1
3 Cross references
95 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta1

Ensembl ID : ENSSTUG00000030950
Gene Symbol: GABRB1
3 Cross references
96 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).